Argentina Received First batch of 300,000 doses of Sputnik V vaccine

This is one of the largest single deliveries of a COVID vaccine to Latin American country

Moscow, December 24, 2020 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund)announces the delivery of the first batch of 300,000 doses ofSputnik V, the world’s first registered vaccine against coronavirus, to Argentina.

This delivery is part of the total supply volume of 10 million doses agreed by RDIF and the Government of Argentina on December 10, 2020. On December 23, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) granted Sputnik V emergency use authorization and approved the use of the vaccine in the country.

The supply of 300,000 doses to Argentina is one of the largest single shipment of a COVID vaccine to any country in Latin America.

Sputnik V has a unique set of parameters making it one of the most competitive vaccines globally. On December 14, the Gamaleya National Center and RDIF announced the results of the third and final control point analysis of data obtained 21 days after administering the first dose to volunteers. The efficacy of the vaccine is 91.4%. The calculation was based on the analysis of data of volunteers (n = 22,714) who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol. The vaccine was confirmed to be highly effective, at a rate of above 90%, at each of the three control points of the clinical trials (20, 39 and 78 confirmed cases of novel coronavirus infection among volunteers both in the placebo group and in the group that received the vaccine).

The vaccine demonstrated 100% efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group.

The cost of one dose is less than $10 for international markets and the production of the lyophilized (dry) form of the vaccine, which is stored at a temperature of +2 to +8 degrees Celsius, enables the vaccine to be easily distributed to international markets.